Previous nontargeted serum metabolomic analysis revealed that the level of DA3S was significantly elevated in the serum of PD patients, with a fold change of 13.85 and a highly significant FDR, indicating that it is among the most markedly altered metabolites in patients with PD [ 27 ].
← all excerpts
Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson's disease: insights from the PPMI cohort.
1
—
—